Menu
← Oncology Approval Tracker
FDA DECISION ·
Modeyso
dordaviprone · Jazz Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults and children age 1 year or older with progressive H3 K27M-mutated diffuse midline glioma after prior therapy.
LAMPGEN ANALYSIS
Why it matters
The decision introduced a systemic treatment for progressive H3 K27M-mutated diffuse midline glioma on accelerated approval.
What research teams should watch
Coordinate access to molecular neuropathology, imaging review, and age-appropriate oral dosing across referral sites.
PRIMARY RECORDS